The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a large global outbreak and become a major global public health concern. It is still spreading rapidly to many countries despite extensive implementation of control measures. So far, SARS-CoV-2 has affected more than 2,544,792 patients and resulted in more than 175,694 deaths all over the world. Rapid and accurate detection of novel coronavirus SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), plays a crucial role in facilitating early intervention and reducing rapid transmission of the virus. Reverse transcription polymerase chain reaction (RT-PCR)-based molecular detection is highly sensitive and specific method and has been widely used for early diagnostics of the COVID-19 disease. However, it relies on expensive instruments, and well-trained personnel, which are not suitable for point of care settings such as drive-thru testing sites, home care, small clinics with limited infrastructure and resources. Here, we propose to develop and validate a rapid, low cost, CRISPR-based molecular detection technology for early diagnostics of the COVID-19 disease at the point of care. To achieve the goal, we have assembled a highly interdisciplinary research team (e.g., bioengineer, clinician, virologist and industry partner). We will use this supplemental project to generate preliminary data to: i) develop and optimize our point of care diagnostic technology for SARS-CoV-2 detection, and ii) evaluate and validate the clinical feasibility of our technology for early diagnostics of the COVID-19 disease by using COVID-19 patient samples. The pilot-test data obtained in this project will provide a basis for future large-scale research and commercial applications. If successful, such simple and rapid diagnostic technology will open a new pathway for cost-effective, molecular detection of the COVID-19 disease at the point of care.

Public Health Relevance

The objective of this project is to clinically evaluate and validate a point of care diagnostic technology for SARS-CoV-2 detection by using COVID-19 patient samples. The results obtained using our point of care diagnostic system will be read by naked eye or recorded, and reported by a smartphone.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
3R01EB023607-05S1
Application #
10152033
Study Section
Program Officer
Lash, Tiffani Bailey
Project Start
2020-06-10
Project End
2021-06-09
Budget Start
2020-06-10
Budget End
2021-06-09
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Connecticut
Department
Type
Schools of Dentistry/Oral Hygn
DUNS #
022254226
City
Farmington
State
CT
Country
United States
Zip Code
06030
Kadimisetty, Karteek; Song, Jinzhao; Doto, Aoife M et al. (2018) Fully 3D printed integrated reactor array for point-of-care molecular diagnostics. Biosens Bioelectron 109:156-163